10 Jul 2013 Posted in ABPI statement By Press Office
Stephen Whitehead, Chief Executive of the ABPI, said:
"We welcome the chance to take part in a debate about the future of the NHS as a key partner in healthcare, delivering innovative medicines that help to treat patients and which play an important role in helping to transform how care is delivered.
"This report again confirms the need for a change in the way some services are delivered in the NHS to guarantee its long term economic viability and as a means of driving up standards of patient care. It is clear that there needs to be greater emphasis on treating people at home through community care and medicines. As part of this redesign, there also needs to be a move away from maintaining some expensive and unnecessary hospitals which place considerable strain on NHS finances.
"The effective use of modern medicines has a vital role to play in a more efficient and effective NHS. By investing in innovative treatments, we can keep people healthier for longer in their own homes and thereby significantly improve their quality of life, whilst minimising the need for expensive hospital care."
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.